Using Nanotechnology to target cancer cells.​

​

Tumors are live entities and their survival depends on the immune system, surrounding cells, orchestrated pathways, and processes. Choosing more than one target from the pool of tumor–stroma interactions, such as the angiogenic blood vessel network, which ensures tumor survival, growth and metastases, can profoundly benefit therapeutic approaches. 

The prevailing new rationale aims at the development of targeted selective therapies to the tumor microenvironment on the basis of characterized mechanisms, with the possibility of directing and concentrating a therapeutic agent only at the desired target site, while improving access to intracellular sites of action. 

Our main aim is to design and address the mechanistic base of non-viral carriers aiming at targeting and efficient intracellular delivery of drugs and nucleic acids to the tumor microenvironment, for cancer treatment.